Haemonetics (HAE) Financials

$67.85 +0.24 (+0.35%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$67.88 +0.03 (+0.04%)

As of 05/29/2025 04:56 PM Eastern

Annual Income Statements for Haemonetics

This table shows Haemonetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/30/2024	4/1/2023	4/2/2022	4/3/2021	3/28/2020	3/30/2019	3/31/2018	4/1/2017	4/2/2016	3/28/2015
Net Income / (Loss) Attributable to Common Shareholders	118	115	43	79	77	55	46	-26	-56	17
Consolidated Net Income / (Loss)	118	115	43	79	77	55	46	-26	-56	17
Net Income / (Loss) Continuing Operations	118	115	43	79	77	55	46	-26	-56	17
Total Pre-Tax Income	152	141	64	73	87	74	60	-27	-53	31
Total Operating Income	165	156	81	90	103	84	56	-19	-44	41
Total Gross Profit	692	615	506	398	485	418	412	378	406	434
Total Revenue	1,309	1,169	993	870	988	968	904	886	909	910
Operating Revenue	1,309	1,169	993	870	988	968	904	886	909	910
Total Cost of Revenue	618	554	488	473	504	550	492	508	503	476
Operating Cost of Revenue	618	554	488	473	504	550	492	508	503	476
Total Operating Expenses	527	459	425	308	381	334	356	398	450	394
Selling, General & Admin Expense	432	377	340	275	282	273	317	302	317	337
Research & Development Expense	54	50	47	33	31	36	39	38	45	54
Amortization Expense	32	33	47	33	26	25	-	-	-	-
Other Operating Expenses / (Income)	-2.00	-0.38	-9.60	-33	-8.08	0.00	-	-	-	-
Impairment Charge	10	0.00	0.00	-	51	0.00	0.00	59	92	5.44
Total Other Income / (Expense), net	-13	-15	-17	-17	-16	-9.91	3.48	-8.10	-9.47	-9.38
Other Income / (Expense), net	-13	-15	-17	-17	-16	-9.91	3.48	-8.10	-9.47	-9.38
Income Tax Expense	34	26	20	-6.56	11	19	14	-1.21	2.16	14
Basic Earnings per Share	$2.32	$2.27	$0.85	$1.57	$1.51	$1.07	$0.86	($0.51)	($1.09)	$0.33
Weighted Average Basic Shares Outstanding	50.71M	50.78M	51.05M	50.69M	50.69M	51.53M	52.76M	51.52M	50.91M	51.53M
Diluted Earnings per Share	$2.29	$2.24	$0.84	$1.55	$1.48	$1.04	$0.85	($0.51)	($1.09)	$0.32
Weighted Average Diluted Shares Outstanding	51.40M	51.42M	51.35M	51.29M	51.82M	52.94M	53.50M	51.52M	50.91M	52.09M
Weighted Average Basic & Diluted Shares Outstanding	50.84M	50.54M	51.28M	50.95M	50.39M	51.21M	53M	51.50M	51M	51.20M

This table shows Haemonetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022	7/2/2022
Net Income / (Loss) Attributable to Common Shareholders	37	34	38	20	31	25	41	29	33	33	20
Consolidated Net Income / (Loss)	37	34	38	20	31	25	41	29	33	33	20
Net Income / (Loss) Continuing Operations	37	34	38	20	31	25	41	29	33	33	20
Total Pre-Tax Income	50	45	47	23	44	33	52	33	42	41	25
Total Operating Income	59	52	40	30	46	35	54	35	43	47	31
Total Gross Profit	194	187	175	176	178	171	167	156	159	158	142
Total Revenue	349	346	336	343	336	318	311	304	305	297	261
Operating Revenue	349	346	336	343	336	318	311	304	305	297	261
Total Cost of Revenue	155	158	161	167	158	148	144	148	147	140	119
Operating Cost of Revenue	155	158	161	167	158	148	144	148	147	140	119
Total Operating Expenses	135	136	135	146	132	135	114	121	115	111	111
Selling, General & Admin Expense	106	107	108	122	112	115	93	98	95	92	92
Research & Development Expense	16	17	14	16	13	13	13	16	13	11	11
Amortization Expense	12	12	12	10	6.91	7.22	7.47	7.97	8.08	8.22	8.37
Total Other Income / (Expense), net	-9.11	-6.99	6.96	-6.53	-1.95	-2.47	-2.07	-2.63	-1.06	-5.67	-5.27
Other Income / (Expense), net	-9.11	-6.99	6.96	-6.53	-1.95	-2.47	-2.07	-2.63	-1.06	-5.67	-5.27
Income Tax Expense	12	11	8.34	3.05	13	7.92	11	3.24	9.28	7.86	5.62
Basic Earnings per Share	$0.75	$0.66	$0.75	$0.40	$0.62	$0.49	$0.81	$0.58	$0.65	$0.65	$0.39
Weighted Average Basic Shares Outstanding	50.29M	50.90M	50.94M	50.71M	50.77M	50.73M	50.54M	50.78M	50.51M	50.95M	51.22M
Diluted Earnings per Share	$0.74	$0.66	$0.74	$0.40	$0.61	$0.48	$0.80	$0.58	$0.64	$0.64	$0.38
Weighted Average Diluted Shares Outstanding	50.64M	51.24M	51.56M	51.40M	51.45M	51.40M	51.34M	51.42M	51.22M	51.56M	51.68M
Weighted Average Basic & Diluted Shares Outstanding	50.24M	50.22M	51.18M	50.84M	50.79M	50.74M	50.71M	50.54M	50.45M	50.61M	51.32M

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/30/2024	4/1/2023	4/2/2022	4/3/2021	3/28/2020	3/30/2019	3/31/2018	4/1/2017	4/2/2016	3/28/2015
Net Change in Cash & Equivalents	-106	25	67	55	-32	-11	41	24	-46	-32
Net Cash From Operating Activities	182	273	172	109	158	159	220	160	122	127
Net Cash From Continuing Operating Activities	182	273	172	109	158	159	220	160	122	127
Net Income / (Loss) Continuing Operations	118	115	43	79	77	55	46	-26	-56	17
Consolidated Net Income / (Loss)	118	115	43	79	77	55	46	-26	-56	17
Depreciation Expense	97	93	98	84	110	109	89	90	90	86
Amortization Expense	6.52	1.97	3.40	0.56	0.60	-	-	-	-	-
Non-Cash Adjustments To Reconcile Net Income	46	26	22	23	60	40	7.91	96	121	25
Changes in Operating Assets and Liabilities, net	-86	36	5.89	-78	-89	-46	78	0.39	-34	-0.72
Net Cash From Investing Activities	-322	-144	-86	-425	-57	-116	-63	-73	-105	-122
Net Cash From Continuing Investing Activities	-322	-144	-86	-425	-57	-116	-63	-73	-105	-122
Purchase of Property, Plant & Equipment	-66	-110	-97	-37	-49	-119	-75	-76	-102	-122
Acquisitions	-244	-2.85	-2.50	-435	-35	0.00	0.00	-	-3.00	0.00
Purchase of Investments	-16	-33	0.00	0.00	-	-	-	-	-	-
Sale of Property, Plant & Equipment	1.81	1.61	2.02	1.82	17	2.81	2.76	2.82	0.64	0.45
Divestitures	1.50	0.85	11	45	9.81	0.00	9.00	0.00	0.00	-
Net Cash From Financing Activities	38	-100	-16	367	-131	-51	-121	-60	-63	-33
Net Cash From Continuing Financing Activities	38	-100	-16	367	-131	-51	-121	-60	-63	-33
Repayment of Debt	-72	-61	-18	-35	-13	-267	-62	-93	-22	-9.58
Repurchase of Common Equity	0.00	-75	0.00	0.00	-175	-160	-100	0.00	-61	-39
Issuance of Debt	110	330	0.00	440	45	363	0.67	0.00	2.27	1.40
Other Financing Activities, net	0.48	-295	1.76	-37	12	13	40	33	18	14
Effect of Exchange Rate Changes	-3.19	-3.94	-2.98	4.18	-1.87	-3.32	3.94	-1.57	-0.01	-4.06
Cash Interest Paid	21	14	6.19	7.82	13	13	7.66	7.85	8.51	8.50
Cash Income Taxes Paid	53	18	24	12	12	8.21	9.08	6.96	7.83	11

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022	7/2/2022
Net Change in Cash & Equivalents	22	-45	166	-15	-157	65	1.25	60	-17	26	-45
Net Cash From Operating Activities	44	49	-27	64	-0.54	99	19	80	64	87	42
Net Cash From Continuing Operating Activities	44	49	-27	64	-0.54	99	19	80	64	87	42
Net Income / (Loss) Continuing Operations	37	34	38	20	31	25	41	29	33	33	20
Consolidated Net Income / (Loss)	37	34	38	20	31	25	41	29	33	33	20
Depreciation Expense	29	29	29	28	24	23	23	24	24	23	22
Amortization Expense	3.34	3.74	5.24	4.13	-	-	0.00	0.87	0.79	-0.48	0.80
Non-Cash Adjustments To Reconcile Net Income	3.27	12	-16	7.83	11	21	4.99	7.37	9.50	6.38	3.22
Changes in Operating Assets and Liabilities, net	-29	-30	-85	4.12	-67	30	-50	18	-2.39	25	-4.35
Net Cash From Investing Activities	-17	-23	-139	-13	-269	-25	-15	-18	-37	-31	-58
Net Cash From Continuing Investing Activities	-17	-23	-139	-13	-269	-25	-15	-18	-37	-31	-58
Purchase of Property, Plant & Equipment	-8.55	-9.43	-5.66	-9.69	-15	-9.11	-7.68	-12	-17	-36	-45
Purchase of Investments	-3.18	-9.83	-0.54	-5.42	-3.13	-1.00	-6.00	-	-20	-3.00	-10
Sale of Property, Plant & Equipment	0.25	0.19	20	0.55	0.34	0.52	0.40	-6.09	0.16	7.04	0.50
Other Investing Activities, net	-5.90	-2.54	-4.21	-	-7.65	-16	-1.98	-	-	-	-
Net Cash From Financing Activities	1.38	-75	334	-64	109	-7.17	-0.60	-1.60	-50	-26	-23
Net Cash From Continuing Financing Activities	1.38	-75	334	-64	109	-7.17	-0.60	-1.60	-50	-26	-23
Repayment of Debt	-187	-65	-10	-64	-3.45	-3.51	-2.61	-1.76	-332	277	-4.39
Other Financing Activities, net	3.09	0.21	-356	0.11	2.88	-3.67	2.02	0.16	2.08	-278	-19
Effect of Exchange Rate Changes	-6.21	4.20	-1.45	-2.70	3.02	-1.53	-1.97	0.46	4.57	-4.03	-4.93

This table presents Haemonetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/30/2024	4/1/2023	4/2/2022	4/3/2021	3/28/2020	3/30/2019	3/31/2018	4/1/2017	4/2/2016	3/28/2015
Total Assets	2,196	1,935	1,860	1,820	1,267	1,275	1,237	1,239	1,319	1,485
Total Current Assets	769	770	756	694	604	576	521	510	488	558
Cash & Equivalents	179	284	259	192	137	169	180	140	115	161
Accounts Receivable	207	179	159	128	165	185	151	153	157	146
Inventories, net	317	259	293	323	270	194	161	177	187	211
Prepaid Expenses	66	47	44	51	31	27	29	41	29	40
Plant, Property, & Equipment, net	311	311	258	218	253	344	332	324	338	322
Total Noncurrent Assets	1,115	854	845	909	410	355	384	405	493	606
Goodwill	565	466	467	466	211	211	211	211	268	334
Intangible Assets	406	276	310	365	133	128	157	178	204	245
Noncurrent Deferred & Refundable Income Taxes	7.74	5.24	4.47	6.01	3.93	4.36	3.96	3.99	7.06	16
Other Noncurrent Operating Assets	136	107	63	71	62	12	12	12	14	11
Total Liabilities & Shareholders' Equity	2,196	1,935	1,860	1,820	1,267	1,275	1,237	1,239	1,319	1,485
Total Liabilities	1,236	1,117	1,110	1,088	680	607	485	499	598	659
Total Current Liabilities	300	252	442	253	275	236	385	211	186	189
Short-Term Debt	10	12	214	17	77	28	194	61	43	22
Accounts Payable	73	64	58	50	51	63	55	43	40	48
Current Employee Benefit Liabilities	81	64	49	48	49	53	70	44	36	51
Other Current Liabilities	136	112	121	139	98	92	66	64	67	68
Total Noncurrent Liabilities	935	865	668	835	405	371	100	288	412	471
Long-Term Debt	798	754	559	691	306	322	59	254	365	406
Noncurrent Deferred & Payable Income Tax Liabilities	63	36	29	44	11	20	6.53	12	21	33
Other Noncurrent Operating Liabilities	75	75	80	100	89	29	34	22	26	32
Total Equity & Noncontrolling Interests	960	818	749	732	587	668	752	740	722	826
Total Preferred & Common Equity	960	818	749	732	587	668	752	740	722	826
Total Common Equity	960	818	749	732	587	668	752	740	722	826
Common Stock	635	595	573	603	554	537	504	483	440	427
Retained Earnings	360	253	202	158	79	161	267	290	316	420
Accumulated Other Comprehensive Income / (Loss)	-36	-30	-26	-30	-45	-30	-19	-33	-35	-22

This table presents Haemonetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	12/28/2024	9/28/2024	6/29/2024	12/30/2023	9/30/2023	7/1/2023	12/31/2022	10/1/2022	7/2/2022	1/1/2022
Total Assets	2,531	2,525	2,541	2,200	2,011	1,962	1,878	1,865	1,821	1,831
Total Current Assets	1,006	956	979	765	866	802	706	716	688	729
Cash & Equivalents	321	299	344	194	351	286	224	241	215	237
Accounts Receivable	212	214	201	212	174	177	181	172	146	155
Inventories, net	360	382	374	304	286	289	256	255	278	306
Prepaid Expenses	113	61	59	55	55	50	45	48	48	32
Plant, Property, & Equipment, net	286	300	302	319	308	304	313	308	288	239
Total Noncurrent Assets	1,239	1,269	1,260	1,117	838	856	859	841	844	863
Goodwill	605	616	613	555	465	466	466	465	466	468
Intangible Assets	466	488	495	429	251	268	284	293	303	324
Noncurrent Deferred & Refundable Income Taxes	8.00	9.08	9.37	5.07	4.75	4.88	4.84	4.28	4.55	6.05
Other Noncurrent Operating Assets	160	156	142	127	117	117	103	80	71	65
Total Liabilities & Shareholders' Equity	2,531	2,525	2,541	2,200	2,011	1,962	1,878	1,865	1,821	1,831
Total Liabilities	1,624	1,646	1,636	1,257	1,118	1,098	1,102	1,136	1,050	1,101
Total Current Liabilities	253	274	260	262	264	237	227	262	180	355
Short-Term Debt	5.08	5.43	5.11	14	14	14	9.95	58	6.85	144
Accounts Payable	63	69	77	57	80	78	64	61	58	51
Current Employee Benefit Liabilities	46	49	41	59	46	33	52	45	30	39
Other Current Liabilities	139	150	137	132	125	112	101	98	85	121
Total Noncurrent Liabilities	1,371	1,372	1,376	995	853	861	875	874	870	745
Long-Term Debt	1,220	1,220	1,218	857	749	751	757	760	763	633
Noncurrent Deferred & Payable Income Tax Liabilities	61	63	65	62	35	37	40	36	33	26
Other Noncurrent Operating Liabilities	90	90	92	76	70	72	78	78	74	86
Total Equity & Noncontrolling Interests	907	879	905	943	894	865	776	729	770	731
Total Preferred & Common Equity	907	879	905	943	894	865	776	729	770	731
Total Common Equity	907	879	905	943	894	865	776	729	770	731
Common Stock	570	545	561	628	617	610	588	565	581	567
Retained Earnings	392	369	387	340	309	284	224	204	222	193
Accumulated Other Comprehensive Income / (Loss)	-56	-35	-43	-24	-33	-30	-36	-40	-33	-29

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	3/30/2024	4/1/2023	4/2/2022	4/3/2021	3/28/2020	3/30/2019	3/31/2018	4/1/2017	4/2/2016	3/28/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.01%	17.67%	14.10%	-11.94%	2.16%	7.04%	2.01%	-2.50%	-0.17%	-3.00%
EBITDA Growth	7.99%	43.63%	4.45%	-20.34%	8.19%	22.95%	139.14%	70.59%	-68.87%	-0.78%
EBIT Growth	7.40%	122.23%	-12.73%	-16.34%	18.36%	23.48%	317.03%	48.56%	-271.40%	-14.38%
NOPAT Growth	0.23%	131.33%	-43.73%	7.79%	45.37%	45.46%	416.34%	55.89%	-239.94%	-50.97%
Net Income Growth	1.87%	166.05%	-45.42%	3.85%	39.09%	20.73%	273.49%	52.74%	-428.93%	-51.93%
EPS Growth	2.23%	166.67%	-45.81%	4.73%	42.31%	22.35%	266.67%	53.21%	-440.63%	-52.24%
Operating Cash Flow Growth	-33.44%	58.51%	58.32%	-31.23%	-0.67%	-27.71%	37.94%	31.08%	-4.18%	-8.85%
Free Cash Flow Firm Growth	-277.05%	137.50%	112.15%	-395.87%	169.56%	-69.83%	52.78%	78.99%	310.31%	-63.19%
Invested Capital Growth	22.28%	2.84%	1.33%	49.82%	-1.93%	2.75%	-9.70%	-9.83%	-7.22%	0.95%
Revenue Q/Q Growth	3.06%	3.49%	4.19%	-1.52%	-1.08%	1.65%	0.61%	-1.59%	1.78%	-1.58%
EBITDA Q/Q Growth	-0.84%	7.45%	39.06%	-26.08%	-0.14%	9.13%	96.92%	-44.99%	-32.91%	-0.52%
EBIT Q/Q Growth	-5.72%	13.94%	204.37%	-40.37%	0.16%	13.06%	563.45%	-217.20%	-50.52%	-0.30%
NOPAT Q/Q Growth	-4.56%	17.90%	26.15%	-19.23%	-2.13%	19.34%	492.40%	-160.38%	-63.64%	-43.82%
Net Income Q/Q Growth	-7.12%	20.51%	91.98%	-26.51%	-4.03%	19.44%	361.19%	-262.78%	-11.67%	-43.70%
EPS Q/Q Growth	-7.29%	21.08%	95.35%	-26.89%	-2.63%	20.93%	342.86%	-259.38%	-10.10%	-44.83%
Operating Cash Flow Q/Q Growth	-7.87%	4.42%	62.88%	-29.19%	19.46%	-18.85%	11.68%	-10.47%	-1.66%	3.11%
Free Cash Flow Firm Q/Q Growth	3.31%	51.56%	109.94%	-413.61%	2.06%	-35.52%	5.16%	-0.29%	-37.61%	414.00%
Invested Capital Q/Q Growth	-1.91%	-1.47%	-0.60%	48.46%	1.52%	1.99%	-1.84%	-6.43%	-2.60%	-3.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.83%	52.63%	50.90%	45.70%	49.02%	43.15%	45.57%	42.71%	44.66%	47.72%
EBITDA Margin	19.53%	20.25%	16.59%	18.12%	20.03%	18.92%	16.47%	7.03%	4.02%	12.88%
Operating Margin	12.60%	13.35%	8.13%	10.31%	10.46%	8.63%	6.21%	-2.19%	-4.84%	4.45%
EBIT Margin	11.60%	12.10%	6.41%	8.38%	8.82%	7.61%	6.60%	-3.10%	-5.88%	3.42%
Profit (Net Income) Margin	8.98%	9.87%	4.37%	9.13%	7.74%	5.69%	5.04%	-2.96%	-6.12%	1.86%
Tax Burden Percent	77.41%	81.61%	68.17%	108.99%	87.81%	74.72%	76.42%	95.60%	104.05%	54.22%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	22.59%	18.39%	31.83%	-8.99%	12.19%	25.28%	23.58%	0.00%	0.00%	45.78%
Return on Invested Capital (ROIC)	8.84%	9.94%	4.39%	9.41%	10.80%	7.46%	4.93%	-1.41%	-2.92%	2.02%
ROIC Less NNEP Spread (ROIC-NNEP)	7.02%	7.54%	2.12%	4.58%	4.12%	1.63%	7.07%	-6.83%	-11.78%	0.04%
Return on Net Nonoperating Assets (RNNOA)	4.39%	4.79%	1.47%	2.64%	1.40%	0.29%	1.18%	-2.19%	-4.26%	0.01%
Return on Equity (ROE)	13.22%	14.73%	5.86%	12.05%	12.20%	7.75%	6.11%	-3.60%	-7.18%	2.03%
Cash Return on Invested Capital (CROIC)	-11.21%	7.14%	3.07%	-30.48%	12.74%	4.75%	15.13%	8.93%	4.57%	1.08%
Operating Return on Assets (OROA)	7.35%	7.45%	3.46%	4.72%	6.86%	5.86%	4.82%	-2.15%	-3.81%	2.08%
Return on Assets (ROA)	5.69%	6.08%	2.36%	5.15%	6.02%	4.38%	3.68%	-2.05%	-3.96%	1.13%
Return on Common Equity (ROCE)	13.22%	14.73%	5.86%	12.05%	12.20%	7.75%	6.11%	-3.60%	-7.18%	2.03%
Return on Equity Simple (ROE_SIMPLE)	12.25%	14.11%	5.79%	10.86%	13.03%	8.24%	6.06%	-3.55%	-7.70%	2.05%
Net Operating Profit after Tax (NOPAT)	128	127	55	98	91	62	43	-14	-31	22
NOPAT Margin	9.75%	10.90%	5.54%	11.24%	9.18%	6.45%	4.75%	-1.53%	-3.38%	2.41%
Net Nonoperating Expense Percent (NNEP)	1.82%	2.40%	2.27%	4.83%	6.68%	5.83%	-2.14%	5.43%	8.86%	1.98%
Cost of Revenue to Revenue	47.17%	47.37%	49.10%	54.30%	50.98%	56.85%	54.43%	57.29%	55.34%	52.28%
SG&A Expenses to Revenue	32.98%	32.23%	34.25%	31.62%	28.53%	28.26%	35.02%	34.05%	34.90%	37.04%
R&D to Revenue	4.16%	4.29%	4.71%	3.77%	3.12%	3.69%	4.34%	4.24%	4.95%	5.95%
Operating Expenses to Revenue	40.23%	39.28%	42.77%	35.39%	38.56%	34.52%	39.36%	44.90%	49.50%	43.27%
Earnings before Interest and Taxes (EBIT)	152	141	64	73	87	74	60	-27	-53	31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	256	237	165	158	198	183	149	62	36	117
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.52	5.10	4.35	7.78	8.65	6.68	5.20	2.85	2.49	2.76
Price to Tangible Book Value (P/TBV)	0.00	54.93	0.00	0.00	20.87	13.55	10.17	6.01	7.20	9.21
Price to Revenue (P/Rev)	3.31	3.57	3.29	6.54	5.14	4.61	4.33	2.38	1.97	2.50
Price to Earnings (P/E)	36.87	36.17	75.24	71.65	66.35	81.10	85.80	0.00	0.00	134.72
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.71%	2.76%	1.33%	1.40%	1.51%	1.23%	1.17%	0.00%	0.00%	0.74%
Enterprise Value to Invested Capital (EV/IC)	3.12	3.58	2.99	4.98	6.40	5.47	4.82	2.50	2.06	2.33
Enterprise Value to Revenue (EV/Rev)	3.79	3.98	3.80	7.13	5.38	4.80	4.41	2.58	2.30	2.79
Enterprise Value to EBITDA (EV/EBITDA)	19.42	19.67	22.92	39.36	26.88	25.36	26.76	36.70	57.19	21.70
Enterprise Value to EBIT (EV/EBIT)	32.68	32.93	59.37	85.16	61.07	63.05	66.81	0.00	0.00	81.62
Enterprise Value to NOPAT (EV/NOPAT)	38.89	36.56	68.63	63.48	58.65	74.38	92.83	0.00	0.00	115.73
Enterprise Value to Operating Cash Flow (EV/OCF)	27.31	17.05	21.93	57.07	33.64	29.15	18.08	14.30	17.13	20.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	50.92	98.11	0.00	49.70	116.86	30.26	26.51	43.35	216.76
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.84	0.94	1.03	0.97	0.65	0.52	0.34	0.43	0.57	0.52
Long-Term Debt to Equity	0.83	0.92	0.75	0.94	0.52	0.48	0.08	0.34	0.51	0.49
Financial Leverage	0.62	0.64	0.70	0.58	0.34	0.18	0.17	0.32	0.36	0.31
Leverage Ratio	2.32	2.42	2.48	2.34	2.03	1.77	1.66	1.75	1.81	1.80
Compound Leverage Factor	2.32	2.42	2.48	2.34	2.03	1.77	1.66	1.75	1.81	1.80
Debt to Total Capital	45.70%	48.36%	50.79%	49.16%	39.45%	34.39%	25.21%	29.85%	36.12%	34.12%
Short-Term Debt to Total Capital	0.58%	0.74%	14.06%	1.18%	7.94%	2.72%	19.31%	5.79%	3.85%	1.72%
Long-Term Debt to Total Capital	45.12%	47.61%	36.73%	47.98%	31.51%	31.68%	5.91%	24.06%	32.27%	32.41%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	54.30%	51.65%	49.21%	50.84%	60.55%	65.61%	74.79%	70.15%	63.88%	65.88%
Debt to EBITDA	3.16	3.24	4.69	4.49	1.93	1.91	1.70	5.05	11.18	3.65
Net Debt to EBITDA	2.46	2.03	3.12	3.27	1.24	0.99	0.49	2.81	8.03	2.28
Long-Term Debt to EBITDA	3.12	3.19	3.40	4.38	1.54	1.76	0.40	4.07	9.99	3.47
Debt to NOPAT	6.33	6.01	14.05	7.23	4.21	5.61	5.91	-23.19	-13.26	19.47
Net Debt to NOPAT	4.93	3.78	9.34	5.27	2.70	2.90	1.71	-12.91	-9.52	12.16
Long-Term Debt to NOPAT	6.25	5.92	10.16	7.06	3.37	5.17	1.38	-18.69	-11.85	18.49
Altman Z-Score	3.42	3.59	2.77	4.16	5.89	5.86	6.16	3.80	2.97	3.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.56	3.06	1.71	2.74	2.20	2.44	1.35	2.42	2.63	2.96
Quick Ratio	1.28	1.84	0.95	1.26	1.10	1.50	0.86	1.38	1.47	1.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-162	91	39	-317	107	40	132	86	48	12
Operating Cash Flow to CapEx	281.85%	251.47%	182.31%	308.89%	494.68%	137.14%	305.87%	217.89%	119.75%	104.44%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.62	0.54	0.56	0.78	0.77	0.73	0.69	0.65	0.61
Accounts Receivable Turnover	6.79	6.90	6.92	5.95	5.64	5.76	5.95	5.72	6.00	5.87
Inventory Turnover	2.14	2.00	1.58	1.59	2.17	3.10	2.91	2.79	2.53	2.33
Fixed Asset Turnover	4.21	4.11	4.17	3.70	3.31	2.86	2.76	2.68	2.76	3.07
Accounts Payable Turnover	9.00	9.05	8.98	9.36	8.83	9.27	10.02	12.28	11.42	9.33
Days Sales Outstanding (DSO)	53.77	52.86	52.72	61.38	64.66	63.42	61.36	63.80	60.83	62.23
Days Inventory Outstanding (DIO)	170.40	182.12	230.38	228.94	168.25	117.83	125.27	130.85	144.47	156.73
Days Payable Outstanding (DPO)	40.57	40.32	40.66	39.01	41.32	39.36	36.44	29.71	31.97	39.11
Cash Conversion Cycle (CCC)	183.60	194.66	242.44	251.31	191.60	141.89	150.19	164.94	173.32	179.85
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,589	1,299	1,264	1,247	832	849	826	915	1,014	1,093
Invested Capital Turnover	0.91	0.91	0.79	0.84	1.18	1.16	1.04	0.92	0.86	0.84
Increase / (Decrease) in Invested Capital	290	36	17	415	-16	23	-89	-100	-79	10
Enterprise Value (EV)	4,964	4,656	3,778	6,209	5,323	4,643	3,984	2,285	2,087	2,544
Market Capitalization	4,335	4,175	3,263	5,694	5,078	4,462	3,910	2,110	1,794	2,276
Book Value per Share	$18.90	$16.21	$14.66	$14.40	$11.67	$13.09	$14.08	$14.22	$14.19	$16.04
Tangible Book Value per Share	($0.22)	$1.51	($0.55)	($1.97)	$4.84	$6.46	$7.19	$6.75	$4.90	$4.80
Total Capital	1,768	1,584	1,523	1,439	970	1,018	1,006	1,054	1,130	1,254
Total Debt	808	766	774	708	382	350	254	315	408	428
Total Long-Term Debt	798	754	559	691	306	322	59	254	365	406
Net Debt	629	481	514	515	245	181	74	175	293	267
Capital Expenditures (CapEx)	64	109	94	35	32	116	72	73	102	122
Debt-free, Cash-free Net Working Capital (DFCFNWC)	300	245	268	265	268	199	151	220	231	230
Debt-free Net Working Capital (DFNWC)	479	530	528	457	406	368	331	360	346	391
Net Working Capital (NWC)	469	518	314	440	329	340	136	299	303	369
Net Nonoperating Expense (NNE)	10	12	12	18	14	7.41	-2.66	13	25	5.08
Net Nonoperating Obligations (NNO)	629	481	514	515	245	181	74	175	293	267
Total Depreciation and Amortization (D&A)	104	95	101	85	111	109	89	90	90	86
Debt-free, Cash-free Net Working Capital to Revenue	22.91%	20.98%	27.03%	30.42%	27.16%	20.53%	16.66%	24.86%	25.40%	25.25%
Debt-free Net Working Capital to Revenue	36.57%	45.32%	53.15%	52.51%	41.05%	38.04%	36.59%	40.61%	38.07%	42.90%
Net Working Capital to Revenue	35.79%	44.32%	31.59%	50.55%	33.26%	35.18%	15.10%	33.73%	33.29%	40.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.32	$2.27	$0.85	$1.57	$1.51	$1.07	$0.86	($0.51)	($1.09)	$0.33
Adjusted Weighted Average Basic Shares Outstanding	50.71M	50.78M	51.05M	50.69M	50.69M	51.53M	52.76M	51.52M	50.91M	51.53M
Adjusted Diluted Earnings per Share	$2.29	$2.24	$0.84	$1.55	$1.48	$1.04	$0.85	($0.51)	($1.09)	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	51.40M	51.42M	51.35M	51.29M	51.82M	52.94M	53.50M	51.52M	50.91M	52.09M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.84M	50.54M	51.28M	50.95M	50.39M	51.21M	52.21M	52.46M	51.04M	51.68M
Normalized Net Operating Profit after Tax (NOPAT)	136	127	55	63	135	62	43	27	31	23
Normalized NOPAT Margin	10.37%	10.90%	5.54%	7.22%	13.68%	6.45%	4.75%	3.10%	3.37%	2.56%
Pre Tax Income Margin	11.60%	12.10%	6.41%	8.38%	8.82%	7.61%	6.60%	-3.10%	-5.88%	3.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	64.99%	0.00%	0.00%	228.68%	290.81%	219.43%	0.00%	-109.72%	231.01%

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022	7/2/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.66%	8.59%	7.98%	12.77%	10.14%	6.96%	19.08%	14.87%	17.53%	24.01%	14.41%
EBITDA Growth	21.79%	39.06%	8.67%	-3.78%	1.47%	-12.76%	53.11%	40.10%	17.73%	44.66%	111.50%
EBIT Growth	13.37%	36.16%	-9.45%	-28.24%	4.27%	-20.04%	102.36%	112.87%	34.52%	106.10%	947.54%
NOPAT Growth	35.91%	46.08%	-23.50%	-17.97%	-3.39%	-29.12%	77.95%	160.21%	27.97%	106.72%	2,365.39%
Net Income Growth	20.02%	35.82%	-6.50%	-30.68%	-5.17%	-24.97%	106.48%	201.64%	41.80%	123.46%	546.27%
EPS Growth	21.31%	37.50%	-7.50%	-31.03%	-4.69%	-25.00%	110.53%	205.26%	42.22%	120.69%	522.22%
Operating Cash Flow Growth	8,204.81%	-50.75%	-243.67%	-19.51%	-100.84%	13.88%	-54.55%	16.99%	3.17%	100.27%	2,599.58%
Free Cash Flow Firm Growth	45.42%	-1,777.38%	-1,778.60%	-6,250.16%	-1,831.34%	43.49%	280.15%	4.44%	96.56%	104.60%	96.83%
Invested Capital Growth	11.79%	38.29%	32.79%	22.28%	22.84%	-0.05%	1.39%	2.84%	3.75%	1.45%	2.91%
Revenue Q/Q Growth	0.88%	2.78%	-2.07%	2.09%	5.68%	2.20%	2.27%	-0.29%	2.63%	13.78%	-1.34%
EBITDA Q/Q Growth	5.95%	-4.23%	46.95%	-19.26%	20.98%	-25.16%	30.11%	-13.86%	4.01%	31.34%	19.06%
EBIT Q/Q Growth	11.66%	-4.30%	99.51%	-46.82%	34.10%	-36.36%	58.13%	-22.73%	2.84%	61.05%	66.33%
NOPAT Q/Q Growth	13.33%	19.80%	25.38%	-20.16%	21.81%	-37.26%	34.45%	-5.97%	-10.63%	57.51%	96.60%
Net Income Q/Q Growth	10.83%	-11.84%	88.41%	-34.81%	25.43%	-39.31%	39.68%	-10.81%	-0.76%	67.01%	104.06%
EPS Q/Q Growth	12.12%	-10.81%	85.00%	-34.43%	27.08%	-40.00%	37.93%	-9.38%	0.00%	68.42%	100.00%
Operating Cash Flow Q/Q Growth	-10.36%	278.05%	-142.79%	11,966.85%	-100.54%	419.35%	-76.03%	23.59%	-25.99%	107.27%	-38.29%
Free Cash Flow Firm Q/Q Growth	68.17%	-12.87%	-54.85%	1.88%	-1,078.16%	12.95%	685.81%	70.16%	-172.67%	241.81%	-210.74%
Invested Capital Q/Q Growth	0.35%	1.12%	12.31%	-1.91%	24.14%	-2.90%	3.42%	-1.47%	1.01%	-1.50%	4.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	55.53%	54.25%	52.03%	51.24%	52.90%	53.59%	53.73%	51.33%	51.98%	53.07%	54.41%
EBITDA Margin	23.61%	22.48%	24.12%	16.07%	20.09%	17.55%	23.97%	18.84%	21.81%	21.52%	18.64%
Operating Margin	16.94%	14.96%	11.83%	8.72%	13.67%	11.10%	17.24%	11.58%	14.18%	15.71%	11.77%
EBIT Margin	14.32%	12.94%	13.90%	6.82%	13.09%	10.32%	16.57%	10.72%	13.83%	13.80%	9.75%
Profit (Net Income) Margin	10.76%	9.79%	11.41%	5.93%	9.29%	7.83%	13.18%	9.65%	10.79%	11.16%	7.60%
Tax Burden Percent	75.11%	75.68%	82.15%	86.99%	70.96%	75.87%	79.55%	90.06%	78.02%	80.85%	77.97%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	24.89%	24.32%	17.85%	13.01%	29.04%	24.14%	20.45%	9.94%	21.98%	19.15%	22.03%
Return on Invested Capital (ROIC)	10.19%	9.91%	8.28%	6.88%	8.39%	7.99%	12.52%	9.51%	9.65%	10.62%	7.20%
ROIC Less NNEP Spread (ROIC-NNEP)	9.32%	9.12%	9.13%	5.85%	8.16%	7.61%	12.20%	9.04%	9.49%	9.83%	6.50%
Return on Net Nonoperating Assets (RNNOA)	7.96%	6.88%	7.00%	3.66%	5.79%	4.63%	7.72%	5.74%	6.82%	8.02%	5.24%
Return on Equity (ROE)	18.15%	16.79%	15.29%	10.53%	14.17%	12.63%	20.24%	15.25%	16.47%	18.64%	12.44%
Cash Return on Invested Capital (CROIC)	-2.83%	-23.75%	-20.63%	-11.21%	-11.40%	10.39%	9.55%	7.14%	4.66%	6.32%	3.33%
Operating Return on Assets (OROA)	8.31%	7.76%	8.23%	4.32%	8.16%	6.60%	10.68%	6.60%	8.42%	8.16%	5.54%
Return on Assets (ROA)	6.25%	5.88%	6.76%	3.76%	5.79%	5.01%	8.49%	5.95%	6.57%	6.60%	4.32%
Return on Common Equity (ROCE)	18.15%	16.79%	15.29%	10.53%	14.17%	12.63%	20.24%	15.25%	16.47%	18.64%	12.44%
Return on Equity Simple (ROE_SIMPLE)	14.34%	14.09%	12.69%	0.00%	13.42%	14.35%	15.80%	0.00%	12.34%	11.80%	8.79%
Net Operating Profit after Tax (NOPAT)	44	39	33	26	33	27	43	32	34	38	24
NOPAT Margin	12.72%	11.32%	9.71%	7.59%	9.70%	8.42%	13.71%	10.43%	11.06%	12.70%	9.17%
Net Nonoperating Expense Percent (NNEP)	0.87%	0.79%	-0.84%	1.02%	0.23%	0.38%	0.32%	0.48%	0.15%	0.79%	0.71%
Return On Investment Capital (ROIC_SIMPLE)	2.08%	-	-	-	1.80%	-	-	-	-	-	-
Cost of Revenue to Revenue	44.47%	45.75%	47.97%	48.76%	47.10%	46.41%	46.27%	48.67%	48.02%	46.93%	45.59%
SG&A Expenses to Revenue	30.54%	30.95%	32.20%	35.45%	33.22%	36.24%	30.03%	32.11%	31.01%	30.94%	35.27%
R&D to Revenue	4.54%	4.78%	4.30%	4.62%	3.95%	3.98%	4.06%	5.14%	4.16%	3.66%	4.17%
Operating Expenses to Revenue	38.59%	39.29%	40.21%	42.52%	39.22%	42.49%	36.49%	39.75%	37.81%	37.36%	42.64%
Earnings before Interest and Taxes (EBIT)	50	45	47	23	44	33	52	33	42	41	25
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	82	78	81	55	68	56	75	57	67	64	49
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.30	4.65	4.65	4.52	4.60	5.08	4.98	5.10	5.13	5.21	4.48
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	25.56	32.96	54.93	156.19	0.00	2,160.19
Price to Revenue (P/Rev)	2.84	3.00	3.15	3.31	3.42	3.67	3.53	3.57	3.52	3.51	3.36
Price to Earnings (P/E)	29.95	32.99	36.61	36.87	34.28	35.41	31.51	36.17	41.57	44.15	50.98
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.34%	3.03%	2.73%	2.71%	2.92%	2.82%	3.17%	2.76%	2.41%	2.27%	1.96%
Enterprise Value to Invested Capital (EV/IC)	2.65	2.78	2.85	3.12	3.10	3.80	3.56	3.58	3.43	3.35	3.02
Enterprise Value to Revenue (EV/Rev)	3.49	3.68	3.81	3.79	3.95	4.00	3.92	3.98	4.01	4.04	3.91
Enterprise Value to EBITDA (EV/EBITDA)	16.07	17.65	19.40	19.42	19.64	19.47	18.21	19.67	20.54	20.81	21.04
Enterprise Value to EBIT (EV/EBIT)	29.13	31.54	34.60	32.68	31.14	31.10	28.55	32.93	36.45	38.63	43.49
Enterprise Value to NOPAT (EV/NOPAT)	33.70	38.40	43.09	38.89	37.50	36.72	32.78	36.56	41.88	43.52	49.51
Enterprise Value to Operating Cash Flow (EV/OCF)	37.14	58.98	37.60	27.31	25.42	18.89	19.12	17.05	17.30	16.86	18.56
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	36.54	37.51	50.92	74.97	53.43	92.22
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.35	1.39	1.35	0.84	0.92	0.85	0.88	0.94	0.99	1.12	1.00
Long-Term Debt to Equity	1.35	1.39	1.35	0.83	0.91	0.84	0.87	0.92	0.98	1.04	0.99
Financial Leverage	0.85	0.75	0.77	0.62	0.71	0.61	0.63	0.64	0.72	0.82	0.81
Leverage Ratio	2.56	2.56	2.54	2.32	2.37	2.39	2.31	2.42	2.46	2.57	2.50
Compound Leverage Factor	2.56	2.56	2.54	2.32	2.37	2.39	2.31	2.42	2.46	2.57	2.50
Debt to Total Capital	57.46%	58.23%	57.47%	45.70%	48.00%	46.03%	46.94%	48.36%	49.70%	52.87%	49.99%
Short-Term Debt to Total Capital	0.24%	0.26%	0.24%	0.58%	0.76%	0.82%	0.83%	0.74%	0.64%	3.76%	0.44%
Long-Term Debt to Total Capital	57.22%	57.97%	57.23%	45.12%	47.24%	45.21%	46.11%	47.61%	49.06%	49.11%	49.54%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	42.54%	41.77%	42.53%	54.30%	52.00%	53.97%	53.06%	51.65%	50.30%	47.13%	50.01%
Debt to EBITDA	4.10	4.32	4.67	3.16	3.41	3.00	2.91	3.24	3.48	3.89	4.04
Net Debt to EBITDA	3.03	3.26	3.35	2.46	2.65	1.62	1.83	2.03	2.46	2.74	2.91
Long-Term Debt to EBITDA	4.08	4.30	4.65	3.12	3.36	2.94	2.86	3.19	3.44	3.61	4.01
Debt to NOPAT	8.60	9.39	10.37	6.33	6.51	5.65	5.24	6.01	7.10	8.13	9.51
Net Debt to NOPAT	6.35	7.10	7.45	4.93	5.06	3.05	3.29	3.78	5.03	5.73	6.86
Long-Term Debt to NOPAT	8.56	9.35	10.33	6.25	6.41	5.55	5.15	5.92	7.01	7.55	9.43
Altman Z-Score	2.62	2.61	2.68	3.22	3.21	3.68	3.61	3.41	3.32	3.11	3.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.97	3.49	3.76	2.56	2.92	3.28	3.38	3.06	3.11	2.73	3.81
Quick Ratio	2.10	1.87	2.10	1.28	1.55	1.99	1.95	1.84	1.79	1.57	2.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-147	-461	-408	-263	-269	27	24	-4.15	-14	19	-13
Operating Cash Flow to CapEx	527.62%	528.16%	0.00%	701.57%	-3.77%	1,153.41%	262.21%	442.14%	385.95%	300.99%	93.38%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.60	0.59	0.63	0.62	0.64	0.64	0.62	0.61	0.59	0.57
Accounts Receivable Turnover	6.49	7.02	7.05	6.79	6.47	7.17	7.53	6.90	6.72	6.93	7.35
Inventory Turnover	1.93	1.93	1.91	2.14	2.14	2.17	2.04	2.00	1.90	1.76	1.61
Fixed Asset Turnover	4.54	4.48	4.40	4.21	4.02	4.03	4.11	4.11	4.09	4.08	4.08
Accounts Payable Turnover	10.71	8.64	8.19	9.00	9.92	8.28	8.50	9.05	9.29	9.56	9.09
Days Sales Outstanding (DSO)	56.28	51.99	51.80	53.77	56.42	50.92	48.46	52.86	54.31	52.68	49.69
Days Inventory Outstanding (DIO)	188.74	188.96	190.64	170.40	170.75	168.19	178.92	182.12	191.87	207.13	226.75
Days Payable Outstanding (DPO)	34.08	42.27	44.59	40.57	36.79	44.08	42.92	40.32	39.28	38.19	40.16
Cash Conversion Cycle (CCC)	210.94	198.69	197.85	183.60	190.39	175.04	184.46	194.66	206.90	221.62	236.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,811	1,805	1,785	1,589	1,620	1,305	1,344	1,299	1,319	1,306	1,325
Invested Capital Turnover	0.80	0.88	0.85	0.91	0.86	0.95	0.91	0.91	0.87	0.84	0.79
Increase / (Decrease) in Invested Capital	191	500	441	290	301	-0.67	18	36	48	19	37
Enterprise Value (EV)	4,800	5,010	5,085	4,964	5,016	4,954	4,782	4,656	4,523	4,376	4,007
Market Capitalization	3,896	4,084	4,206	4,335	4,339	4,543	4,303	4,175	3,980	3,799	3,452
Book Value per Share	$18.06	$17.17	$17.81	$18.90	$18.59	$17.62	$17.11	$16.21	$15.33	$14.21	$15.02
Tangible Book Value per Share	($3.27)	($4.40)	($3.99)	($0.22)	($0.81)	$3.51	$2.58	$1.51	$0.50	($0.56)	$0.03
Total Capital	2,132	2,104	2,129	1,768	1,814	1,656	1,630	1,584	1,543	1,547	1,540
Total Debt	1,225	1,225	1,224	808	871	762	765	766	767	818	770
Total Long-Term Debt	1,220	1,220	1,218	798	857	749	751	754	757	760	763
Net Debt	904	926	879	629	677	411	479	481	543	577	555
Capital Expenditures (CapEx)	8.30	9.24	-15	9.13	14	8.59	7.28	18	17	29	45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	437	388	379	300	323	264	293	245	265	271	299
Debt-free Net Working Capital (DFNWC)	758	687	724	479	517	615	578	530	489	512	514
Net Working Capital (NWC)	753	682	719	469	503	602	565	518	479	454	507
Net Nonoperating Expense (NNE)	6.84	5.29	-5.71	5.68	1.38	1.87	1.65	2.37	0.82	4.59	4.11
Net Nonoperating Obligations (NNO)	904	926	879	629	677	411	479	481	543	577	555
Total Depreciation and Amortization (D&A)	32	33	34	32	24	23	23	25	24	23	23
Debt-free, Cash-free Net Working Capital to Revenue	31.81%	28.51%	28.43%	22.91%	25.43%	21.31%	24.01%	20.98%	23.50%	24.97%	29.16%
Debt-free Net Working Capital to Revenue	55.17%	50.50%	54.25%	36.57%	40.70%	49.64%	47.45%	45.32%	43.34%	47.23%	50.11%
Net Working Capital to Revenue	54.80%	50.10%	53.87%	35.79%	39.62%	48.54%	46.34%	44.32%	42.45%	41.86%	49.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.75	$0.66	$0.75	$0.40	$0.62	$0.49	$0.81	$0.58	$0.65	$0.65	$0.39
Adjusted Weighted Average Basic Shares Outstanding	50.29M	50.90M	50.94M	50.71M	50.77M	50.73M	50.54M	50.78M	50.51M	50.95M	51.22M
Adjusted Diluted Earnings per Share	$0.74	$0.66	$0.74	$0.40	$0.61	$0.48	$0.80	$0.58	$0.64	$0.64	$0.38
Adjusted Weighted Average Diluted Shares Outstanding	50.64M	51.24M	51.56M	51.40M	51.45M	51.40M	51.34M	51.42M	51.22M	51.56M	51.68M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.24M	50.22M	51.18M	50.84M	50.79M	50.74M	50.71M	50.54M	50.45M	50.61M	51.32M
Normalized Net Operating Profit after Tax (NOPAT)	44	39	33	26	33	27	43	32	34	38	24
Normalized NOPAT Margin	12.72%	11.32%	9.71%	7.59%	9.70%	8.42%	13.71%	10.43%	11.06%	12.70%	9.17%
Pre Tax Income Margin	14.32%	12.94%	13.90%	6.82%	13.09%	10.32%	16.57%	10.72%	13.83%	13.80%	9.75%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	57.66%	60.58%	0.00%	0.00%	0.00%	0.00%	0.00%	64.99%	78.32%	87.16%	0.00%

Frequently Asked Questions About Haemonetics' Financials

When does Haemonetics's financial year end?

According to the most recent income statement we have on file, Haemonetics' fiscal year ends in March. Their fiscal year 2024 ended on March 30, 2024.

How has Haemonetics' net income changed over the last 9 years?

Haemonetics' net income appears to be on an upward trend, with a most recent value of $117.56 million in 2024, rising from $16.90 million in 2015. The previous period was $115.40 million in 2023. Check out Haemonetics' forecast to explore projected trends and price targets.

What is Haemonetics's operating income?

Haemonetics's total operating income in 2024 was $164.88 million, based on the following breakdown:

Total Gross Profit: $691.55 million
Total Operating Expenses: $526.67 million

How has Haemonetics revenue changed over the last 9 years?

Over the last 9 years, Haemonetics' total revenue changed from $910.37 million in 2015 to $1.31 billion in 2024, a change of 43.8%.

How much debt does Haemonetics have?

Haemonetics' total liabilities were at $1.24 billion at the end of 2024, a 10.6% increase from 2023, and a 87.4% increase since 2015.

How much cash does Haemonetics have?

In the past 9 years, Haemonetics' cash and equivalents has ranged from $115.12 million in 2016 to $284.47 million in 2023, and is currently $178.80 million as of their latest financial filing in 2024.

How has Haemonetics' book value per share changed over the last 9 years?

Over the last 9 years, Haemonetics' book value per share changed from 16.04 in 2015 to 18.90 in 2024, a change of 17.8%.

Related Companies

This page (NYSE:HAE) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Financials

Frequently Asked Questions About Haemonetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Financials

Annual Income Statements for Haemonetics

Quarterly Income Statements for Haemonetics

Annual Cash Flow Statements for Haemonetics

Quarterly Cash Flow Statements for Haemonetics

Annual Balance Sheets for Haemonetics

Quarterly Balance Sheets for Haemonetics

Annual Metrics And Ratios for Haemonetics

Quarterly Metrics And Ratios for Haemonetics

Frequently Asked Questions About Haemonetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools